Medicine Recommendations

Green

Green

Green

Green

Green

Green

Green

Green

Green

Dapagliflozin

Date Posted: 01 - Dec - 2016

BNF chapter: Endocrine system

Expand/Collapse

Triple therapy for treating type 2 diabetes (NICE TA418)

NICE TA418 - Dapagliflozin in triple therapy for treating type 2 diabetes

MHRA Drug Safety Update - SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin): risk of diabetic ketoacidosis

Green

Green

Green

Green

Green

Green

Green

Green

Green

Dapagliflozin

Date Posted: 19 - Apr - 2022

BNF chapter: Endocrine system

Expand/Collapse

Chronic kidney disease (NICE TA775)

NICE TA775 - Dapagliflozin for treating chronic kidney disease

Green (R)(Restricted)

Green

Green (R)(Restricted)

Green (R)(Restricted)

Green

Green (R)(Restricted)

Green (R)(Restricted)

Green

Green (R)(Restricted)

Dapagliflozin

Date Posted: 01 - Dec - 2016

BNF chapter: Endocrine system

Expand/Collapse

In combination therapy for treating type 2 diabetes (NICE TA288)

NICE TA288 - Dapagliflozin in combination therapy for treating type 2 diabetes

MHRA Drug Safety Update - SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin): risk of diabetic ketoacidosis

Amber 0

Amber 0

Amber 0

Amber 0

Amber 0

Amber 0

Amber 0

Amber 0

Amber 0

Dapagliflozin

Date Posted: 20 - Jul - 2023

BNF chapter: Endocrine system

Expand/Collapse

Treating chronic heart failure with preserved or mildly reduced ejection fraction (NICE TA902)

NICE TA 902 - Dapagliflozin for treating chronic heart failure with preserved or mildly reduced ejection fraction

Green

Green

Green

Green

Green

Green

Green

Green

Green

Dapagliflozin

Date Posted: 01 - Jun - 2016

BNF chapter: Endocrine system

Expand/Collapse

Monotherapy for treating type 2 diabetes (NICE TA390)

NICE TA390 - Canagliflozin, dapagliflozin and empagliflozin as monotherapies for treating type 2 diabetes

MHRA Drug Safety Update - SGLT2 inhibitors (canagliflozin, dapagliflozin, empagliflozin): risk of diabetic ketoacidosis

Amber 0

Amber 0

Amber 0

Amber 0

Amber 0

Amber 0

Amber 0

Amber 0

Amber 0

Dapagliflozin

Date Posted: 11 - Mar - 2021

BNF chapter: Cardiovascular system

Expand/Collapse

NICE TA679 - for treating chronic heart failure with reduced ejection fraction

Black

Black

Black

Amber 0

Black

Black

Amber 0

Black

Amber 0

Dapoxetine

Date Posted: 01 - Jan - 2015

BNF chapter: Genito-urinary system

Expand/Collapse

Treatment of premature ejaculation (PE) in men 18-64 years of age

Green (R)(Restricted)

Green (R)(Restricted)

Green (R)(Restricted)

Green (R)(Restricted)

Green (R)(Restricted)

Green (R)(Restricted)

Green (R)(Restricted)

Green (R)(Restricted)

Green (R)(Restricted)

Daridorexant

Date Posted: 30 - Apr - 2024

BNF chapter: Central nervous system

Expand/Collapse

Treating long-term insomnia (NICE TA922)

NICE TA922 - Daridorexant for treating long-term insomnia

Green

Amber 0

Green

Green

Amber 0

Green

Green

Green

Pending

Darifenacin

Date Posted: 01 - Feb - 2015

BNF chapter: Genito-urinary system

Expand/Collapse

Urinary frequency, urgency, and incontinence

Black

Black

Black

Black

Black

Black

Black

Black

Black

Darvadstrocel

Date Posted: 01 - Feb - 2019

BNF chapter: Gastro-intestinal system

Expand/Collapse

Darvadstrocel for treating complex perianal fistulas in Crohn’s disease (TA556)

NICE TA556 - Darvadstrocel for treating complex perianal fistulas in Crohn’s disease

Amber 0

Amber 0

Amber 0

Amber 0

Amber 0

Amber 0

Amber 0

Pending

Pending

Deflazacort

Date Posted: 01 - Oct - 2014

BNF chapter: Endocrine system

Expand/Collapse

Suppression of inflammatory and allergic disorders

Amber 0

Amber 0

Amber 0

Amber 0

Amber 0

Amber 0

Amber 0

Amber 0

Amber 0

Degarelix

Date Posted: 28 - Feb - 2023

BNF chapter: Immune system and Malignant Disease

Expand/Collapse

treatment of adult male patients with advanced hormonedependent prostate cancer - patients without spinal metastases

Amber 0

Amber 0

Amber 0

Amber 0

Amber 0

Amber 0

Amber 0

Amber 0

Amber 0

Degarelix

Date Posted: 01 - Sep - 2016

BNF chapter: Immune system and Malignant Disease

Expand/Collapse

Degarelix for treating advanced hormone-dependent prostate cancer (NICE TA404)

Amber 0

Amber 0

Amber 0

Amber 0

Amber 0

Amber 0

Amber 0

Amber 0

Pending

Demeclocycline hydrochloride

Date Posted: 01 - Oct - 2014

BNF chapter: Endocrine system

Expand/Collapse

Hyponatraemia

Amber 1

Amber 1

Amber 1

Amber 1

Amber 1

Amber 1

Amber 1

Amber 1

Amber 1

Denosumab

Date Posted: 01 - Dec - 2018

BNF chapter: Endocrine system

Expand/Collapse

Denosumab for treatment of Glucocorticoid-induced osteoporosis

MHRA Drug Safety Update - Denosumab (Xgeva▼, Prolia); intravenous bisphosphonates: osteonecrosis of the jaw—further measures to minimise risk

MHRA Drug Safety Update - Denosumab: updated recommendations

MHRA Drug Safety Update - Denosumab 60 mg (Prolia▼)

Amber 1

Amber 1

Amber 1

Amber 1

Amber 1

Amber 1

Amber 1

Amber 1

Amber 1

Denosumab

Date Posted: 01 - Feb - 2018

BNF chapter: Endocrine system

Expand/Collapse

Prevention of osteoporotic fractures in men

MHRA Drug Safety Update - Denosumab (Xgeva▼, Prolia); intravenous bisphosphonates: osteonecrosis of the jaw—further measures to minimise risk

MHRA Drug Safety Update - Denosumab: updated recommendations

MHRA Drug Safety Update - Denosumab 60 mg (Prolia▼)

Amber 1

Amber 0

Amber 1

Amber 1

Amber 0

Amber 1

Amber 1

Amber 0

Amber 0

Denosumab

Date Posted: 01 - Nov - 2013

BNF chapter: Endocrine system

Expand/Collapse

Prevention of osteoporotic fractures in postmenopausal women (NICE TA204)

MHRA Drug Safety Update - Denosumab (Xgeva▼, Prolia); intravenous bisphosphonates: osteonecrosis of the jaw—further measures to minimise risk

MHRA Drug Safety Update - Denosumab: updated recommendations

MHRA Drug Safety Update - Denosumab 60 mg (Prolia▼)

Amber 1

Amber 1

Amber 1

Amber 1

Amber 1

Amber 1

Amber 1

Amber 1

Amber 1

Denosumab 120mg

Date Posted: 13 - Feb - 2024

BNF chapter: Endocrine system

Expand/Collapse

Prevention of skeletal-related events in adults with bone metastases from solid tumours (NICE TA265)

NICE TA265 - Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours

MHRA Drug Safety Update - Denosumab (Xgeva▼, Prolia); intravenous bisphosphonates: osteonecrosis of the jaw—further measures to minimise risk

MHRA Drug Safety Update - Denosumab: updated recommendations

MHRA Drug Safety Update - Denosumab (Xgeva▼) for advanced malignancies involving bone: study data show new primary malignancies reported more frequently compared to zoledronate

MHRA Drug Denosumab (Xgeva▼) for giant cell tumour of bone: risk of clinically significant hypercalcaemia following discontinuation

Red

Red

Red

Red

Red

Red

Red

Red

Red

Deucravacitinib

Date Posted: 20 - Jul - 2023

BNF chapter: Skin

Expand/Collapse

Deucravacitinib for treating moderate to severe plaque psoriasis

NICE TA 907 - Deucravacitinib for treating moderate to severe plaque psoriasis

Palliative Use Only

Green (R)(Restricted)

Green (R)(Restricted)

Green (R)(Restricted)

Green (R)(Restricted)

Green (R)(Restricted)

Green (R)(Restricted)

Green (R)(Restricted)

Green (R)(Restricted)

Green (R)(Restricted)

Dexamethasone

Date Posted: 24 - Mar - 2022

BNF chapter: Gastro-intestinal system

Expand/Collapse

Bowel obstruction - reduction of tumour oedema associated with bowel obstruction

Breathlessness

Corticosteroids in palliative care - Anorexia, Adjuvant analgesic, Nausea and vomiting associated with chemotherapy, Obstructive syndromes, Raised intracranial pressure, Spinal cord compression

Nausea and vomiting - raised Intracranial Pressure

Palliative care emergencies - SVC obstruction AND Metastatic spinal cord compression